Your session is about to expire
← Back to Search
Combination Eye Drops for Presbyopia
Study Summary
This trial studied the safety of a drug for long-term use to help with presbyopia (age-related vision problems).
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Group 1: Combination ophthalmic solution (LNZ101) dosed bilaterally
- Group 2: Placebo (Vehicle) ophthalmic solution dosed bilaterally
- Group 3: Aceclidine ophthalmic solution dosed bilaterally
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Could I potentially participate in this clinical experiment?
"This trial seeks to enrol 300 participants aged between 45 and 75 years old with presbyopia."
Are applicants younger than 85 years of age being accepted into this research?
"The prerequisites for this experiment restrict the participants to being between 45 and 75 years of age. Additionally, there are 11 trials available for those below 18 and 117 options for individuals over 65."
Are any new volunteers being accepted for this research initiative?
"According to the information on clinicaltrials.gov, this medical investigation is actively recruiting participants. The study was first advertised on February 21st 2023 and has since been amended (most recently March 2nd 2023)."
How many participants have registered for this research endeavor?
"Affirmative. Per clinicaltrials.gov, this research venture is presently searching for volunteers; the study was originally posted on February 21st 2023 and refreshed lastly on March 2nd 2023. 300 people are expected to be enrolled at two distinct centres."
What side effects have been observed with the bilaterally administered Combination ophthalmic solution (LNZ101)?
"Our organisation has rated Combination ophthalmic solution (LNZ101) dosed bilaterally a 3 on the safety scale due to both efficacy evidence and numerous rounds of data supporting its security."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger